Royal Philips NV said new tests on its recalled sleep apnea products showed the vast majority of the devices are unlikely to cause considerable health damage to patients.
(Bloomberg) — Royal Philips NV said new tests on its recalled sleep apnea products showed the vast majority of the devices are unlikely to cause considerable health damage to patients.
Exposure to degraded foam in 95% of the breathing apparatuses is “unlikely to result in an appreciable harm to health in patients,” the Netherlands-based health company said Tuesday, citing its test results. Philips initiated its first recall of potentially faulty sleep apnea products in June 2021, with the US Food & Drug Administration also labeling those as a Class 1 issue, the most serious type.
The new results are “very reassuring and very good news for the patients in our view as for our testing,” Chief Executive Officer Roy Jakobs said in a phone interview. “To our current best knowledge, this does not cause harm.”
Philips was little changed as of 1:34 p.m. local time in Amsterdam after rising as much as 6% after the news.
Several Lawsuits
The company has set aside around €1 billion ($1.1 billion) for the recall of around 5.5 million devices globally and booked additional provisions of €575 million as part of a planned settlement in the US to compensate patients.
Philips is a defendant in several class-action lawsuits and individual personal injury claims in the US. Consumers have accused the company of violating the US Federal Food, Drug and Cosmetic Act, which requires that medical devices be safe and effective. They claim the breathing machines were defectively designed by using foam that could degrade if exposed to moisture.
It’s also being investigated by the US Department of Justice and remains in ongoing discussions with the FDA regarding a proposed consent decree. The company has not yet made any provisions for these matters.
Today’s results may form part of Philips’s defense in looming court cases over health claims. “If people claim otherwise, we will use these test results and point to these test results, that in our view and according to our testing, that we do not see any harm done,” said Jakobs.
The FDA is still considering the data provided by the company and the health authority may reach different conclusions.
“It is hard to know how the data will hold up during future litigation,” Citigroup analyst Veronika Dubajova said in a note. There is still “sizable uncertainty” on the potential costs of upcoming litigation, she said, adding that Citi continues to assume an around €5 billion impact from the consent decree, litigation, and DOJ investigation.
In sleep apnea, breathing stops and starts, which can cause fatigue and longer-term health problems. Philips products designed to improve sleep patterns include its DreamStation CPAP machines and Trilogy ventilators.
(Updates with analyst comment, stock reaction and details throughout)
More stories like this are available on bloomberg.com
©2023 Bloomberg L.P.